Welcome to our dedicated page for Arbutus Biopharma Corporation news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharma Corporation stock.
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection (cHBV). Utilizing its extensive expertise in virology, Arbutus focuses on developing a portfolio of drug candidates with multiple mechanisms of action aimed at curing Hepatitis B virus (HBV) disease. The company's lead RNA interference (RNAi) therapeutic, imdusiran (AB-729), targets HBV proteins to reduce viral antigens and reawaken the host's immune response. Imdusiran is currently undergoing multiple Phase 2a clinical trials, demonstrating promising results in reducing hepatitis B surface antigen (HBsAg) levels and achieving functional cures in a subset of patients.
Arbutus leverages its proprietary lipid nanoparticle (LNP) technology and expertise in RNAi therapeutics to develop innovative treatments. Beyond HBV, the company has a robust pipeline that includes AB-101, an oral PD-L1 inhibitor, currently in Phase 1a/1b trials. This compound aims to enable controlled checkpoint blockade while minimizing systemic safety issues.
Recent clinical data highlight the potential of Arbutus' combination therapies. In the IM-PROVE I trial, imdusiran combined with pegylated interferon alfa-2a (IFN) and nucleos(t)ide analogue (NA) therapy demonstrated sustained HBsAg loss in some patients, suggesting a path toward a functional cure. Another study, IM-PROVE II, showed that combining imdusiran with VTP-300, an immunotherapeutic, resulted in meaningful reductions in HBsAg levels and the discontinuation of NA therapy in a significant number of patients.
Financially, Arbutus maintains a strong position with a cash runway extending into the first quarter of 2026. They are actively involved in ongoing patent litigation to protect their LNP technology, seeking fair compensation for its use in mRNA COVID-19 vaccines by Moderna and Pfizer/BioNTech.
Arbutus continues to engage in strategic collaborations and partnerships to advance its mission of curing HBV and other chronic infectious diseases. For more detailed information, visit www.arbutusbio.com.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in the H.C. Wainwright Bioconnect Virtual Conference from January 10-13, 2022. The virtual fireside chat will feature key executives including William Collier (President and CEO) and Dr. Michael Sofia (Chief Scientific Officer). The chat will start at 7:00 am EST on January 10, 2022, with a webcast available on Arbutus' website. Arbutus is focused on developing therapies for chronic hepatitis B and coronaviruses, including COVID-19.
On December 14, 2021, Antios Therapeutics and Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the dosing of the first patient in a Phase 2a clinical trial evaluating a triple combination treatment for chronic hepatitis B virus (HBV) infection. The study involves 40 patients and aims to assess the efficacy of Antios' ATI-2173 and Arbutus' AB-729 with tenofovir disoproxil fumarate (TDF). This combination therapy seeks to achieve a functional cure for HBV by reducing viral replication and antigens. Both companies express optimism regarding the therapeutic potential of this innovative combination.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has formed a strategic partnership with Qilu Pharmaceutical for the development of AB-729, an RNA interference therapeutic aimed at treating hepatitis B in China, Hong Kong, Macau, and Taiwan. Arbutus will receive an upfront payment of $40 million, with potential milestone payments of up to $245 million and double-digit royalties on sales. Qilu will handle all development and commercialization efforts, marking a significant opportunity for Arbutus to reach a large patient population in a lucrative market.
Arbutus Biopharma Corporation (NASDAQ: ABUS) announced the discovery of small molecules that inhibit the SARS-CoV-2 nsp5 main protease, a significant target for COVID-19 treatment. This achievement marks a milestone in collaboration with X-Chem and Proteros, obtaining a worldwide exclusive license for these compounds. The parties aim to expedite the development of pan-coronavirus therapies. This discovery occurred just six months after initiating their agreement, highlighting Arbutus's commitment to effective antiviral treatments against COVID-19 and future outbreaks.
Arbutus Biopharma (Nasdaq: ABUS) announced promising preliminary data from its ongoing Phase 1a/1b trial of the capsid inhibitor AB-836, aimed at treating chronic hepatitis B virus (cHBV) infection. The trial indicates that AB-836 is generally safe and well-tolerated, showing robust antiviral activity with a significant mean drop in HBV DNA levels. No serious adverse events were reported among healthy subjects or cHBV patients. The study continues, with 16 cHBV patients dosed in Part 3, and more data is expected to be presented in 2022.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the appointment of Dr. Tram Tran to its Board of Directors. Dr. Tran is a prominent liver and viral disease expert with over 20 years of experience in academia and industry. Previously, she held key roles at Gilead Sciences and Cedars-Sinai Medical Center. Her expertise is expected to enhance Arbutus's efforts in developing a cure for chronic hepatitis B and treatments for coronaviruses. President and CEO William Collier expressed confidence that Dr. Tran's knowledge will be instrumental in advancing the company’s portfolio.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced promising long-term safety and efficacy data for its lead compound, AB-729, in treating chronic Hepatitis B. Results from a Phase 1a/1b clinical trial show sustained suppression of HBsAg levels up to 28 weeks post-treatment in patients, with no significant differences between 60 mg and 90 mg dosages. The treatment was well-tolerated, with no serious adverse events reported. Continued analysis of the treatment's impact on nucleos(t)ide analogue therapy is anticipated, as the company aims to transform HBV treatment.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in the virtual fireside chat at the Jefferies London Healthcare Conference on November 18, 2021, at 8:00 am GMT / 3:00 am ET. Key executives, including CEO William Collier and Chief Scientific Officer Dr. Michael Sofia, will present during the event. A webcast will be available through Arbutus' website, with a replay accessible after the conference. The company focuses on developing treatments for chronic hepatitis B virus and coronaviruses, leveraging a diverse pipeline aimed at innovative solutions.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported its Q3 2021 financial results, highlighting key developments in its hepatitis B virus (HBV) treatment pipeline. The company has initiated a Phase 2a trial combining AB-729 with standard NA therapy and Peg-IFNα-2a, aiming for multiple data readouts in Q4 2021. Financially, Arbutus reported a net loss of $24.2 million, a slight increase from $21.8 million year-over-year. The company also extended its cash runway into Q2 2023, with $151.9 million in cash on hand as of September 30, 2021, amidst rising R&D expenses.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the presentation of data on its GalNAc-siRNA, AB-729, at The Liver Meeting® 2021, occurring from November 12-15, 2021. The poster, titled "Low HBsAg levels maintained following cessation of the GalNAc-siRNA, AB-729," indicates that AB-729 is generally safe and demonstrates sustained HBsAg decline in chronic hepatitis B patients. Key findings show maintained HBsAg suppression in some patients for up to 20 weeks post-treatment.
FAQ
What is the current stock price of Arbutus Biopharma Corporation (ABUS)?
What is the market cap of Arbutus Biopharma Corporation (ABUS)?
What is Arbutus Biopharma's primary focus?
What is imdusiran (AB-729)?
What are the key recent achievements of Arbutus Biopharma?
What is the status of Arbutus' financial condition?
What technologies does Arbutus leverage for its treatments?
What are the current projects Arbutus Biopharma is working on?
Has Arbutus formed any strategic partnerships?
What is the significance of Arbutus' patent litigation?
How successful have Arbutus' clinical trials been?
Where can more information about Arbutus Biopharma be found?
